Acadia Pharmaceuticals: Proving The Naysayers Wrong
Today, we are revisiting with mid-cap biopharma Acadia Pharmaceuticals Inc., whose stock surged some 20% last week following Q3 results. The company beat both top and bottom-line expectations and also posted updated FY2024 guidance. Acadia Pharmaceuticals is becoming profitable, has a pristine balance sheet, and is seeing solid growth.
Acadia's Q3 Earnings Beat, Nuplazid & Daybue Drive Revenue Growth
ACAD reports encouraging third-quarter results as earnings and revenues beat estimates. Nuplazid and Daybue sales record year-over-year growth.
ACADIA Pharmaceuticals Inc. (ACAD) Q3 2024 Earnings Conference Call Transcript
ACADIA Pharmaceuticals Inc. (ACAD) Q3 2024 Earnings Conference Call Transcript
Acadia Pharmaceuticals (ACAD) Beats Q3 Earnings and Revenue Estimates
Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.20 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to loss of $0.40 per share a year ago.
Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Acadia (ACAD) Could Beat Earnings Estimates Again
Acadia (ACAD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
ACAD or TECH: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Acadia Pharmaceuticals (ACAD) and Techne (TECH). But which of these two stocks is more attractive to value investors?
Acadia (ACAD) Up 10% Since Last Earnings Report: Can It Continue?
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?
Acadia Pharmaceuticals: Nuplazid Performs In Q2 While Daybue Disappoints Again
Shares of Acadia trended lower this year due to Daybue's poor quarterly sales performance, and also due to Nuplazid's failure in the phase 3 trial in schizophrenia patients. The full-year guidance on Daybue was reduced as Acadia is finding fewer new patients, not because of higher patient churn. With most of the headwinds in the rearview mirror, I expect better performance of Daybue going forward.
Acadia (ACAD) Q2 Earnings Beat, Product Sales Drive Revenues
Acadia (ACAD) reports encouraging second-quarter results as both earnings and revenues beat estimates, driven by higher Nuplazid and Daybue sales.
ACADIA Pharmaceuticals Inc. (ACAD) Q2 2024 Earnings Call Transcript
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Al Kildani - Senior Vice President, Investor Relations and Corporate Communications Steve Davis - President and Chief Executive Officer Brendan Teehan - Chief Operating Officer, Head of Commercial Kimberly Manhard - Senior Vice President, Global Strategic Planning and Execution Mark Schneyer - Chief Financial Officer Parag Meswani - Senior Vice President, Trofinetide Elizabeth Thompson - Executive Vice President, Head of Research and Development Conference Call Participants Ritu Baral - TD Cowen Charles Duncan - Cantor Anish Nikhanj - RBC Capital Markets Joel Beatty - Baird Marc Goodman - Leerink Jeff Hung - Morgan Stanley Keith Tapper - BMO Capital Markets David Hoang - Citigroup Eddie Hickman - Guggenheim Tessa Romero - JPMorgan Operator Good day ladies and gentlemen, and thank you for standing by. Welcome to the ACADIA Pharmaceuticals Second Quarter 2024 Financial Results Conference Call.
Acadia Pharmaceuticals (ACAD) Beats Q2 Earnings and Revenue Estimates
Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.20 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.01 per share a year ago.
